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Abstract
It is a challenge to design randomized trials when it is suspected that a treatment may
benefit only certain subsets of the target population. In such situations, trial designs have been
proposed that modify the population enrolled based on an interim analysis, in a preplanned
manner. For example, if there is early evidence that the treatment only benefits a certain subset
of the population, enrollment may then be restricted to this subset. At the end of such a trial,
it is desirable to draw inferences about the selected population. We focus on constructing
confidence intervals for the average treatment effect in the selected population. Confidence
interval methods that fail to account for the adaptive nature of the design may fail to have
the desired coverage probability. We provide a new procedure for constructing confidence
intervals having at least 95% coverage probability, uniformly over a large class of possible
data generating distributions. We prove an optimality property for our confidence interval
procedure in terms of minimizing the average confidence interval widths.
1 Introduction
We consider the problem of constructing confidence intervals in randomized trial designs that
involve a preplanned rule for changing enrollment criteria based on an interim analysis. Such trial
designs have been proposed in situations where a baseline risk factor is conjectured to be predictive
of treatment benefit (Follmann, 1997; Russek-Cohen and Simon, 1997; Wang et al., 2007; Jennison
and Turnbull, 2007; Wang et al., 2009). As an example of such a predictor, in trials of trastuzumab
for treating metastatic breast cancer, the level of overexpression of human epidermal growth factor
receptor-2 (HER2) has been shown to be predictive of treatment benefit (Slamon et al., 2001).
∗Author: e-mail: mrosenbl@jhsph.edu
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As another example, Kirsch et al. (2008) present suggestive evidence that for a certain class of
antidepressants, a patient’s initial severity of depression may be predictive of treatment benefit.
For concreteness, we focus on two-stage, randomized trial designs of a single treatment versus
control, where the overall population is partitioned into two, prespecified subpopulations. In the
designs we consider, a decision is made at an interim analysis to possibly restrict the enrollment
criteria for the second stage, based on data in the first stage; this is called an enrichment design.
The decision rule in such designs must be specified before the study starts. We allow the population
enrolled in stage two to be subpopulation 1, subpopulation 2, or the combined population. We do
not allow changes to the randomization probabilities, total sample size, or number of treatments.
However, it may be possible to apply our general method for constructing confidence intervals to
some designs with these additional types of adaptation, as we discuss in Section 6.
We focus on the problem of constructing confidence intervals for the average treatment effect
in the population selected for enrollment in stage two. Standard confidence interval procedures
that ignore the adaptive nature of the design may fail to have the desired coverage probability. The
main contributions of this paper are: demonstrating a general method for constructing confidence
intervals that have at least 95% coverage probability, uniformly over a large class of possible data
generating distributions, for this problem; and, proving these confidence intervals have an optimal-
ity property in terms of their average width. To the best of our knowledge, our confidence interval
procedure is the first to have this optimality property, for the enrichment designs we consider.
The confidence intervals we present are centered at the difference ∆ˆS in sample means between
treatment and control arms for the selected population, using all data from both stages from that
population. We compute the minimum factor c by which the standard confidence interval centered
at ∆ˆS must be expanded in order to have, asymptotically, at least 95% coverage probability, uni-
formly over a large class of data generating distributions. Computing this constant is not trivial,
since it is not a priori clear, for a given decision rule, what the least favorable data generating
distribution is, i.e., which distribution requires the largest constant c in order for the corresponding
confidence interval procedure to have coverage probability at least 95%. We show how to compute
the least favorable distribution and the corresponding minimum factor c.
For the enrichment designs we consider, the ratio of average width of our confidence intervals,
compared to naive confidence intervals that ignore the adaptive nature of the design, is never more
than 1.1. Thus, for the adaptive designs we consider, at most a 10% inflation of the standard
confidence interval width is required in order to ensure at least 95% coverage probability. However,
in many cases that we expect to occur in practice, the required inflation is at most 5%, as we
describe in Section 5.
Our results are asymptotic, as the sample sizes in both stages of the design go to infinity.
However, our confidence interval coverage is at least 95% at all sample sizes in the special case
that the outcome is normally distributed.
In Section 2, we present related work. We describe the setup of our problem and the type of
adaptive designs we consider, in Section 3. We then give a confidence interval procedure that has
uniform coverage probability at least 95% for these designs, and that has an optimality property,
in Section 4. The distribution of confidence interval widths from our procedure is examined in
Section 5. We discuss limitations and directions for future research in Section 6.
2
http://biostats.bepress.com/jhubiostat/paper238
2 Related Work
We focus on two-stage designs that allow changes to a trial’s enrollment criteria after an interim
analysis; our goal is to construct a confidence interval for the average treatment effect in the popu-
lation selected for enrollment in stage two. We now describe related work.
Designs that make changes to enrollment criteria based on preplanned rules include those of,
e.g., (Follmann, 1997; Russek-Cohen and Simon, 1997; Wang et al., 2007; Jennison and Turnbull,
2007; Wang et al., 2009; Rosenblum and van der Laan, 2011). However, the aforementioned
papers focus on hypothesis testing rather than on confidence intervals. It is not clear how to invert
the multiple testing procedures from these methods to construct a valid confidence interval for the
selected population, due to the multiple hypotheses involved as well as the adaptive nature of the
design.
Repeated confidence intervals for a single population, under various rules for modifying a trial’s
total sample size, have been constructed, e.g., by (Jennison and Turnbull, 1984; Lehmacher and
Wassmer, 1999; Brannath et al., 2006). Posch et al. (2005) give simultaneous confidence intervals
for adaptive designs with multiple treatments. That is, they give a simultaneous set of confidence
intervals for all the treatments. Analogous ideas could be applied to our setting of adaptive designs
with multiple subpopulations. However, the focus of our paper is constructing confidence intervals
with minimum width for the selected population, rather than simultaneous confidence intervals for
all subpopulations considered.
Sampson and Sill (2005) and Wu et al. (2010) consider drop the loser designs, that is, designs
in which the treatment with the largest estimated treatment effect at the end of stage one is selected
for continued study in stage two. They provide confidence intervals for the selected treatment
that have conservative coverage probability for such designs. These methods could be extended
to trial designs that, instead of continuing the best performing treatment, continue the population
with the largest estimated treatment effect. However, in the context of designs that adapt the
population enrolled, it may not be ideal to always continue the population with largest estimated
treatment effect. For example, if the overall population had a large estimated benefit, but a small
subpopulation had a slightly larger estimated benefit, it may be unwise to give up on the overall
population and only continue enrollment from the small subpopulation. Therefore, drop the loser
designs may not be ideal for changing enrollment criteria. The designs we consider below involve
decision rules that are tailored to population selection, and that allow continued enrollment of the
combined population even when it doesn’t have the largest estimated treatment benefit.
3 Problem setup
3.1 Assumptions on data generating distribution
For each subject i, we collect the following vector of data: (Si,Wi, Ai, Yi), where Si is the sub-
population (1 or 2), Wi is the stage of the trial in which the subject is enrolled (1 or 2), Ai is the
study arm assignment (1 indicating the treatment arm and 0 indicating the control arm), and Yi is
the outcome. We allow the outcome variable Y to be discrete or continuous valued.
3
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The definition of the subpopulations must be a prespecified function of variables measured
prior to randomization. We assume the two subpopulations are disjoint, and together make up the
combined population. For example, subpopulation 1 could be defined as those having a certain
biomarker positive at baseline, and subpopulation 2 would then be the biomarker negative popula-
tion. For each s ∈ {1, 2}, let pis denote the proportion of the overall population in subpopulation
s. We assume that in stage one, the proportion of subjects enrolled in the study from each sub-
population s ∈ {1, 2} is the same as the corresponding population proportion pis. We denote the
total sample size in stage j by nj , for j ∈ {1, 2}; these are fixed at the beginning of the study.
We assume pi1, pi2, n1, n2 are known, non-random quantities. We also assume that neither stage
completely dominates the total sample size, in that we assume the fraction of the sample in stage
one, t1 = n1/(n1 + n2), is between 0.01 and 0.99.
We assume that each subject is enrolled with probability 1/2 to treatment or control, indepen-
dent of the subpopulation Si and stage Wi. For simplicity in what follows, we assume that for each
subpopulation and each stage, exactly half the subjects are assigned to the treatment arm (Ai = 1),
and half to the control arm (Ai = 0). This can be approximately guaranteed by using stratified
block randomization.
We denote the unknown outcome distribution for each subpopulation s ∈ {1, 2} and study arm
a ∈ {0, 1} by Qsa, We assume conditioned on the set of patient subpopulations {Si}, study arm
assignments {Ai}, and trial stages at enrollment {Wi}, that the outcome Yi for each subject i is an
independent draw from the unknown outcome distribution QSiAi .
We denote subpopulation 1, subpopulation 2, and the combined population by the subscripts
1, 2, and ∗, respectively. Denote the mean outcome for subpopulation s ∈ {1, 2} under assignment
to arm a ∈ {0, 1} by µ(Qsa), and denote the corresponding variance by σ2(Qsa). We assume the
variances σ2(Qsa) are known.
We make no assumptions on the forms of the outcome distributions Qsa except that their sup-
port is contained in an interval [−M,M ], for some M > 0, and that the variance of each Qsa is
at least a (small) constant τ > 0. In particular, the means, variances, and other features of these
distributions may differ across treatment arms and subpopulations. We fix M > 0, τ > 0, and
define Q to be the class of data generating distributions Q = (Q10, Q11, Q20, Q21) for which each
Qsa has support contained in the interval [−M,M ], and the variance of each Qsa is at least τ > 0.
We assume each subject’s outcome Yi is measured relatively quickly after enrollment, so that all
outcomes in stage one can be used to determine the enrollment criteria in stage two.
3.2 Definition of average treatment effects
For each subpopulation s ∈ {1, 2}, define the average treatment effect for subpopulation s, on the
risk difference scale, by ∆s(Q) = µ(Qs1)−µ(Qs0). Similarly, for the combined population, define
the average treatment effect on the risk difference scale by ∆∗(Q) = pi1∆1(Q)+(1−pi1)∆2(Q). For
clarity of notation, we sometimes suppress dependence on Q, e.g., writing ∆∗ instead of ∆∗(Q).
Let S denote the population selected to be enrolled in stage two. S = 1 indicates population
1 is enrolled in stage two, S = 2 indicates subpopulation 2 is enrolled in stage two, and S = ∗
indicates both subpopulations are enrolled in stage two in the same proportions as in stage 1. The
total number of subjects enrolled in stage two is set at n2, regardless of which population is selected
4
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to be enrolled in stage two. Below, we describe the set of decision rules for determining S as a
function of stage one data, which will use the statistics defined next.
3.3 Statistics used in decision rule and confidence interval procedure
For each subpopulation s ∈ {1, 2} and stage w ∈ {1, 2}, we denote the difference between the
sample means under treatment and under control by
∆ˆ(w)s =
( ∑
{i:Si=s,Wi=w,Ai=1}
Yi
|{i : Si = s,Wi = w,Ai = 1}|
)
−
( ∑
{i:Si=s,Wi=w,Ai=0}
Yi
|{i : Si = s,Wi = w,Ai = 0}|
)
,
where |B| denotes the number of elements in the set B. Similarly, for the combined population, in
stage w ∈ {1, 2}, we denote the difference in the sample means under treatment and under control
by
∆ˆ(w)∗ =
( ∑
{i:Wi=w,Ai=1}
Yi
|{i : Wi = w,Ai = 1}|
)
−
( ∑
{i:Wi=w,Ai=0}
Yi
|{i : Wi = w,Ai = 0}|
)
= pi1∆ˆ
(w)
1 + (1− pi1)∆ˆ(w)2 .
For the population S selected for enrollment in stage two, let ∆ˆS denote the difference in
sample means between treatment and control arms, pooling all subjects in both stages of the trial
in population S. On the event S = ∗, that is, if the combined population is enrolled in stage two,
then ∆ˆS equals ( ∑
{i:Ai=1}
Yi
|{i : Ai = 1}|
)
−
( ∑
{i:Ai=0}
Yi
|{i : Ai = 0}|
)
=
n1∆ˆ
(1)
∗ + n2∆ˆ
(2)
∗
n1 + n2
,
while if enrollment in stage two consists of n2 subjects from only one of the subpopulations, i.e.,
if S = s ∈ {1, 2}, then ∆ˆS equals( ∑
{i:Si=s,Ai=1}
Yi
|{i : Si = s, Ai = 1}|
)
−
( ∑
{i:Si=s,Ai=0}
Yi
|{i : Si = s, Ai = 0}|
)
=
pisn1∆ˆ
(1)
s + n2∆ˆ
(2)
s
pisn1 + n2
.
We define the stage one z-statistics for subpopulation 1, subpopulation 2, and the combined
population, respectively, as:
Z
(1)
1 =
√
pi1n1
σ1(Q)
∆ˆ
(1)
1 , Z
(1)
2 =
√
pi2n1
σ2(Q)
∆ˆ
(1)
2 , Z
(1)
∗ =
√
n1
σ∗(Q)
∆ˆ(1)∗ ,
where for each s ∈ {1, 2}, σ2s(Q) = 2 {σ2(Qs0) + σ2(Qs1)}, and σ2∗(Q) = pi1σ21(Q) + (1 −
pi1)σ
2
2(Q).
Let ρs denote the covariance between Z
(1)
s and Z
(1)
∗ for each s ∈ {1, 2}. We then have
ρs =
√
pisσs(Q)/σ∗(Q), ρ
2
1 + ρ
2
2 = 1, and Z
(1)
∗ = ρ1Z
(1)
1 + ρ2Z
(1)
2 .
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3.4 Set of decision rules
For concreteness, throughout this paper we focus on the following type of decision rule for stage
two enrollment, for a prespecified constant d:
If Z
(1)
∗ > d, in stage two, continue enrolling from the combined population, in the
same proportions as in stage one. Else, enroll exclusively from the subpopulation
corresponding to the larger of Z
(1)
1 , Z
(1)
2 (with ties broken arbitrarily, e.g., selecting
subpopulation 1).
The general method we give below can be applied to construct confidence intervals for other types
of rules than above, which we discuss in Section 6.
4 Confidence interval procedure with uniform coverage prob-
ability
4.1 Goal of confidence interval procedure
The goal in this paper is to provide a procedure CI for constructing confidence intervals with at
least 95% coverage for the treatment effect in the population selected to be enrolled in stage two
of the trial. The treatment effect for the population selected to be enrolled in stage two is ∆S .
This is a random quantity, since it depends on the selected population S. The confidence interval
procedure can use the following as input: all the data from both stages of the trial, pi1, pi2, n1, n2,
and the outcome variances σ2(Qsa) for each subpopulation s ∈ {1, 2} and study arm a ∈ {0, 1},
since the variances σ2(Qsa) are assumed known.
We seek a function CI from the set of data in both stages of the trial to an interval in R
that, asymptotically as the sample sizes in both stages go to infinity, has at least 95% coverage
probability, uniformly over all possible data generating distributions Q. Formally, we require our
procedure CI to satisfy, for fixed decision rule threshold d and subpopulation proportions pi1, pi2:
lim inf
n1,n2→∞
inf
Q∈Q
PQ,n1,n2(∆S ∈ CI) ≥ 0.95, (1)
where PQ,n1,n2 is the probability distribution defined by data generating distribution Q and stage
one and two sample sizes n1 and n2, respectively.
Though the above criterion is asymptotic, our confidence interval procedure has at least 95%
coverage probability at any sample size, in the special case in which the outcome distributions Qsa
are each normal distributions. We note that standard, normal-based confidence intervals for fixed
(non-adaptive) designs have at least 95% coverage only asymptotically, or in special cases such as
when outcomes are normally distributed.
Our goal is to construct a confidence interval procedure CI satisfying (1). The probability in
(1) is a type of average coverage probability, in that we can write it as a convex combination of
coverage probabilities conditioned on each possible enrollment decision:
PQ,n1,n2(∆S ∈ CI) =
∑
s∈{1,2,∗}
PQ,n1,n2(S = s)PQ,n1,n2(∆s ∈ CI | S = s).
6
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Alternatively, one may wish to have the stronger guarantee of asymptotically conservative condi-
tional coverage probability:
lim inf
n1,n2→∞
inf
Q∈Q
inf
s∈{1,2,∗}
PQ,n1,n2(∆s ∈ CI | S = s) ≥ 0.95. (2)
We focus on constructing confidence intervals that satisfy (1). However, our general method can
be used to determine how much one would need to expand these confidence intervals to meet the
stricter condition (2).
4.2 Confidence interval procedure satisfying (1)
Let NS denote the total sample size, at the end of the trial, for the selected population S. This is a
random variable that equals n1+n2 if the combined population is selected, else it equals pisn1+n2
if subpopulation s ∈ {1, 2} is selected.
We define the naive 95% confidence interval that ignores the adaptive nature of the design as[
∆ˆS − z0.975σS/
√
NS, ∆ˆS + z0.975σS/
√
NS
]
, (3)
for z0.975 the 0.975 quantile of the standard normal distribution. In general this will fail to have
95% coverage probability.
Our modified confidence interval, CI , is defined as
CI =
[
∆ˆS − c(pi1, t1, ρ1)z0.975σS/
√
NS, ∆ˆS + c(pi1, t1, ρ1)z0.975σS/
√
NS
]
, (4)
for c(pi1, t1, ρ1) the solution to an optimization problem we define in (6) below. We provide a short
program in R to compute an approximation to c(pi1, t1, ρ1) in the Supplementary Materials, and we
explore the features of the function c in Section 5. The value c(pi1, t1, ρ1) can be thought of as the
smallest multiplicative factor by which the naive confidence interval (3) that ignores the adaptive
nature of the design needs to be expanded, in order to maintain at least 95% coverage probability,
uniformly over Q, as sample size goes to infinity.
We prove in the Appendix that the confidence interval CI has the desired property (1), that
is, it has asymptotic coverage probability at least 95%, uniformly over the class of data gener-
ating distributions Q. Furthermore, we prove that our expansion factor c is smallest possible, at
every value of (pi1, t1, ρ1). More precisely, we prove that for any continuous function c
′ that maps
(pi1, t1, ρ1) into R, if the confidence interval CI in (4), except replacing c by c
′, has property (1),
then c′(pi1, t1, ρ1) ≥ c(pi1, t1, ρ1) at every (pi1, t1, ρ1).
4.3 Construction of expansion factor c
We first give the intuition behind our construction, given below, of the minimum expansion factor
c(pi1, t1, ρ1) that guarantees asymptotic, uniform coverage probability at least 95%, as expressed
in (1). Fix pi1, t1, ρ1, and consider a candidate value for the expansion factor c(pi1, t1, ρ1). Consider
7
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large sample sizes n1, n2, and any data generating distribution Q ∈ Q for which ρ1(Q) = ρ1. The
coverage probability of CI can be decomposed as:
PQ (∆S ∈ CI) =
∑
s∈{1,2,∗}
PQ(∆S ∈ CI, S = s). (5)
We show in the Appendix that each term PQ(∆S ∈ CI, S = s) in this sum is approximately
the probability that a multivariate normal distribution Gs is in a certain rectangular region Rs;
furthermore, the mean and covariance of Gs and the boundaries of the rectangular region depend
on pi1, t1, ρ1, c, d, and depend on Q only through the non-centrality parameters δs′ = EZ
(1)
s′ =√
pis′n1∆s′/σs′ , for s
′ ∈ {1, 2}. We choose the expansion factor c(pi1, t1, ρ1) to be the smallest
value such that no matter what the values of the non-centrality parameters δ1, δ2, the sum of the
multivariate normal probabilities
∑
s∈{1,2,∗} P (Gs ∈ Rs) is at least 0.95.
We now formally define the function c. Fix the threshold d used in the decision rule from
Section 3.4. For each s ∈ {1, 2, ∗}, let Gs(pi1, t1, ρ1) denote the multivariate normal random vector
in R3 with mean vector (0, 0, 0) and covariance matrix the function of (pi1, t1, ρ1) given in (9)-(11)
in the Appendix. For any c˜ ∈ R, define the following disjoint, rectangular regions of R3:
R1(ρ1, c˜, d, δ1, δ2) = [−c˜z0.975, c˜z0.975]× (−∞, d− (ρ1δ1 + ρ2δ2)]× [(δ2 − δ1)/
√
2,∞).
R2(ρ1, c˜, d, δ1, δ2) = [−c˜z0.975, c˜z0.975]× (−∞, d− (ρ1δ1 + ρ2δ2)]× (−∞, (δ2 − δ1)/
√
2).
R∗(ρ1, c˜, d, δ1, δ2) = [−c˜z0.975, c˜z0.975]× (d− (ρ1δ1 + ρ2δ2),∞)× R.
Define
c(pi1, t1, ρ1) = inf

c˜ > 0 : infδ˜1,δ˜2∈R
∑
s∈{1,2,∗}
P
[
Gs(pi1, t1, ρ1) ∈ Rs(ρ1, c˜, d, δ˜1, δ˜2)
]
≥ 0.95

 .
(6)
In Appendix A.3, we explain how to solve the above non-linear optimization problem, and
therefore compute c(pi1, t1, ρ1), to any desired accuracy, in the following sense: for any pi1, t1, ρ1,
and any tolerance  > 0, we show how to compute a value c satisfying the following two condi-
tions:
i. c ≥ c(pi1, t1, ρ1), which implies the confidence interval procedure CI using c satisfies the
asymptotic, uniform coverage probability condition (1);
ii. c is no larger than  plus the expansion threshold required to obtain uniform coverage prob-
ability at least 0.95+ ; that is, c is no greater than  plus (6) with 0.95 replaced by 0.95+ .
We give a brief overview of the main ideas used in Appendix A.3 to compute c(pi1, t1, ρ1) to
any desired accuracy, in the above sense. For any given vector (pi1, t1, ρ1), any candidate value
c˜, and any δ˜1, δ˜2, one can compute the sum in the right hand side of (6) using statistical software
such as the mvtnorm package in R. To compute inf δ˜1,δ˜2∈R of this sum to any desired accuracy,
one can compute this sum at each pair (δ˜1, δ˜2) in a sufficiently fine grid of values, as described in
8
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Appendix A.3. One can then use binary search over candidate values of c˜ to determine the smallest
value for which the minimum coverage probability is at least 95%, yielding an approximation to
c(pi1, t1, ρ1).
It turns out that the right hand side of (6) does not depend on d, the threshold used in the
decision rule from Section 3.4. This justifies our writing c as a function only of the variables
pi1, t1, ρ1. This is advantageous in that once c(pi1, t1, ρ1) is computed for a given d, it is unnecessary
to recompute it for any other value of d. We also learn that there is no advantage in adjusting d
in the hope of obtaining shorter confidence intervals with uniform coverage probability (assuming
we are using the general type of confidence interval in (4)). The reason for no dependence of the
right hand side of (6) on d is that for fixed ρ1, c˜, d, the set of triples of regions generated by varying
δ˜1, δ˜2: {(
R1(ρ1, c˜, d, δ˜1, δ˜2), R2(ρ1, c˜, d, δ˜1, δ˜2), R3(ρ1, c˜, d, δ˜1, δ˜2)
)}
δ˜1,δ˜2∈R
does not depend on d. This can be seen since for any d, d′, the triple of regions corresponding to
(ρ1, c˜, d, δ˜1, δ˜2) is identical to that corresponding to(
ρ1, c˜, d
′, δ˜1 + (d
′ − d)/(ρ1 + ρ2), δ˜2 + (d′ − d)/(ρ1 + ρ2)
)
.
5 Confidence interval widths
The function c defined in (6) represents the multiplicative factor by which the naive confidence
interval (3) must be expanded in order to achieve at least 95% coverage, uniformly over the class
of possible data generating distributions Q. When c = 1, this indicates no change is needed to the
naive confidence interval that ignores the adaptive nature of the design. In general, the width of
the naive confidence interval must be increased by 100(c− 1)% to maintain at least 95% coverage,
uniformly over Q. We note that the value of the expansion factor c(pi1, t1, ρ1) is always at least 1,
which we prove in Appendix A.1.
The arguments to the function c are pi1, t1, ρ1, which represent the proportion of the population
in subpopulation 1, the proportion of the sample in stage one, and the covariance of the first stage
statistics Z
(1)
1 , Z
(1)
∗ (which is a function of pi1 and the variances σ
2
1(Q), σ
2
2(Q) of the outcome for
each subpopulation), respectively. At different values of these arguments, the required expansion
factor c(pi1, t1, ρ1) can differ.
In Figure 1, we plot the value of the expansion factor c(pi1, t1, ρ1), showing how it varies as
we change each of pi1, t1, and ρ1. We initialized the values of (pi1, t1, ρ1) to (1/2, 1/2, 1/
√
2),
respectively, which corresponds to equal subpopulation sizes, equal sample sizes in each stage of
the trial, and equal variances in the outcome distribution for each subpopulation. We then changed
one variable at a time, and looked at the effect on c(pi1, t1, ρ1). In each plot in Figure 1, we
computed c at 20 points with equally spaced values on the horizontal axis ranging from 0.01 to
0.99.
In Figure 1a, we vary pi1, the proportion of the population in subpopulation 1. The minimum
value of c is 1.03 (here and below, we round all values to two decimal places), which occurs at
pi1 = 1/2; c increases as pi1 moves farther from 1/2. A similar pattern occurs in Figure 1c, where
9
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Figure 1: Plots of the expansion factor c versus the proportion of the population
in subpopulation 1 (pi1), the proportion of the sample in stage one (t1), and the
covariance (ρ1) of the first stage statistics Z
(1)
1 , Z
(1)
∗ , respectively. In each plot, the
vector (pi1, t1, ρ1) is initialized to (1/2, 1/2, 1/
√
2), and then one component of the
vector (pi1, t1, ρ1) is varied while the other two are held fixed.
we vary ρ1, the covariance of the first stage statistics Z
(1)
1 , Z
(1)
∗ . The minimum value of c is 1.04,
which occurs at ρ1 = 1/
√
2, and c increases as ρ1 moves farther from 1/
√
2.
In Figure 1b, we varied t1, the proportion of the sample in stage one. As this proportion
increases from 0.01 to 0.99, the expansion factor c increases from 1 to approximately 1.06. In-
tuitively, the limit as t1 ↓ 0 corresponds to the limit design in which the stage two population is
selected instantaneously after the trial starts, i.e., before any data is collected; therefore, the naive
confidence interval (3) has the desired coverage probability since the population is selected inde-
pendent of the data, and so no expansion is required. Also, the limit as t1 ↑ 1 corresponds to the
limit design in which the population of interest is selected after the trial is over (but based on the
trial data); this is a fixed design with data-dependent parameter selection, and requires inflation of
the standard confidence interval width to obtain coverage probability at least 95%.
In order to explore the range of values the function c can take as (pi1, t1, ρ1) varies, we did a
grid search, computing c at each point in the grid. We used the grid D′ = D ×D ×D, for
D = {0.01, 0.1, 0.2., . . . , 0.8, 0.9, .99}. The largest value of c was 1.10. Also, the smallest cover-
age probability of the naive confidence interval (3) that ignores the adaptive nature of the design
was 93.5%. We emphasize that before our analysis, which uses the general method for deter-
mining the least favorable distribution described in the Appendix, it was unknown how much
under-coverage the naive confidence interval can have for our set of enrichment designs.
If we restrict our grid search to those points in D′ satisfying pi1, ρ1 ∈ [0.2, 0.8] and t1 ≤ 0.5,
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then the maximum value of c is 1.05. We think such values of pi1, ρ1 will be common in practice,
as long as neither subpopulation is very small compared to the other, and as long as the variances
of the outcome distributions in both subpopulations are of the same order of magnitude. However,
this might be violated if the outcome is binary and one population has much smaller risk than the
other. Having t1 ≤ 0.5 can be achieved if the enrollment decision is planned to be made before
half the total number of subjects are enrolled.
6 Discussion
The general method we used can be applied to construct confidence intervals for other types of
decision rules than those in Section 3.4. In general, a decision rule based on the first stage statistics
Z
(1)
1 , Z
(1)
2 , Z
(1)
∗ can be constructed by partitioning R
3 into three regions D1, D2, D∗, where the rule
is that if
(Z
(1)
1 , Z
(1)
2 , Z
(1)
∗ ) ∈ Ds then one enrolls from population s in stage two. If the regions Ds have
simple boundaries and are straightforward to integrate a multivariate normal distriubution over us-
ing standard software, then the method in this paper can be used. However, an important limitation
of the method is that it may not be feasible to implement for complex rules.
It may be possible to extend the above results to designs that allow prespecified changes to the
randomization probabilities and/or total sample size, but this is an area of future research.
In this paper we considered only prespecified decision rules for which population to enroll in
stage two. Another interesting set of designs are flexible designs, where there is no prespecified
decision rule. Posch et al. (2005) and Brannath et al. (2006) present confidence interval procedures
for such designs that have uniform coverage probability under any possible adaptation within the
class of adaptations they allow. Confidence intervals with uniform coverage probability will in
general need larger widths if a flexible design is used, compared to if a prespecified decision rule is
used. It is in interesting open problem to determine the price, in terms of wider confidence interval
widths, that must be paid if one does not specify the decision rule for the design in advance.
Our confidence interval procedure is optimal, as described in Section 4.2, among those that
are symmetric and centered at the difference ∆ˆS in sample means between treatment and control
arms for the selected population, using all data from both stages from that population. However,
it may be possible to reduce the confidence interval widths by considering asymmetric confidence
intervals, or by centering at a different value. This is an open problem for future research.
This research was supported by the National Institutes of Health, U.S.A., and by the U.S. Food
and Drug Administration’s Partnership in Applied Comparative Effectiveness Science (PACES).
Appendix
In Appendix A.1, we prove the confidence interval procedure (4) from Section 4.2 satisfies (1), i.e.,
it has asymptotic, uniform coverage probability at least 95%. Then, in Appendix A.2, we prove
that this function c is smallest possible, at every value of (pi1, t1, ρ1), in that for any continuous
function c′ that maps (pi1, t1, ρ1) into R, if the confidence interval CI in (4), except replacing c
11
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by c′, has property (1), then c′(pi1, t1, ρ1) ≥ c(pi1, t1, ρ1) at every (pi1, t1, ρ1). Lastly, in Appendix
A.3, we show how to compute c(pi1, t1, ρ1), for given values of (pi1, t1, ρ1), to any desired accuracy,
using statistical software.
A.1. Proof that confidence interval procedure (4) satisfies (1)
We prove the confidence interval procedure (4) from Section 4.2 satisfies (1), i.e., it has asymptotic,
uniform coverage probability at least 95%.
We first show that the value of the expansion factor c(pi1, t1, ρ1) is always at least 1. To show
this, consider any c˜ < 1. The sum in (6) converges to Φ(c˜z0.975) − Φ(−c˜z0.975) as δ˜1, δ˜2 both
go to infinity, which follows by the form of the regions R1, R2, R∗ in Section 4.3. Therefore, the
infimum of the sum in (6) over δ˜1, δ˜2 ∈ R is at most Φ(c˜z0.975) − Φ(−c˜z0.975), which is less than
0.95 for c˜ < 1. This implies the inequality to the right of the colon in (6) does not hold for c˜ < 1,
and therefore c(pi1, t1, ρ1) ≥ 1.
We now prove the confidence interval procedure (4) satisfies (1). Fix the decision rule threshold
d from Section 3.4 and the subpopulation proportions pi1, pi2. For any sample sizes n1, n2, and any
data generating distributionQ ∈ Q, the probability that the confidence intervalCI contains ∆S(Q)
is
PQ(∆S(Q) ∈ CI) =
∑
s∈{1,2,∗}
PQ(∆S(Q) ∈ CI, S = s). (7)
We consider the terms in the sum on the right hand side separately for each of s ∈ {1, 2, ∗}. First,
consider the term corresponding to s = 1. We suppress the dependence on Q for notational clarity.
P (∆S ∈ CI, S = 1)
= P (∆1 ∈ CI, S = 1)
= P
(
∆1 ∈ CI, Z(1)∗ ≤ d, Z(1)1 ≥ Z(1)2
)
(8)
= P
(
∆1 ∈ [∆ˆ1 − cz0.975σ1/
√
NS, ∆ˆ1 + cz0.975σ1/
√
NS], Z
(1)
∗ ≤ d, Z(1)1 ≥ Z(1)2
)
= P
(
∆ˆ1 ∈ [∆1 − cz0.975σ1/
√
NS,∆1 + cz0.975σ1/
√
NS], Z
(1)
∗ ≤ d, Z(1)1 ≥ Z(1)2
)
= P
(√
NS
σ1
{
∆ˆ1 −∆1
}
∈ [−cz0.975, cz0.975], Z(1)∗ ≤ d, Z(1)1 ≥ Z(1)2
)
= P
(√
pi1n1 + n2
σ1
{
∆ˆ1 −∆1
}
∈ [−cz0.975, cz0.975], Z(1)∗ ≤ d, Z(1)1 ≥ Z(1)2
)
= P
(√
pi1n1 + n2
σ1
{
∆ˆ1 −∆1
}
∈ [−cz0.975, cz0.975],
Z(1)∗ −
√
n1∆∗
σ∗
≤ d−
√
n1∆∗
σ∗
,
1√
2
{(
Z
(1)
1 −
√
pi1n1∆1
σ1
)
−
(
Z
(1)
2 −
√
pi2n1∆2
σ2
)}
≥
√
pi2n1
2
∆2
σ2
−
√
pi1n1
2
∆1
σ1
)
,
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where (8) follows from our decision rule from Section 3.4.
Denote the random variables on the right hand side of the last equality above by X1, X2, X3,
respectively, that is,
X
(1)
1 =
√
pi1n1 + n2
σ1
{
∆ˆ1 −∆1
}
,
X
(1)
2 = Z
(1)
∗ −
√
n1∆∗
σ∗
,
X
(1)
3 =
1√
2
{(
Z
(1)
1 −
√
pi1n1∆1
σ1
)
−
(
Z
(1)
2 −
√
pi2n1∆2
σ2
)}
.
The vector (X
(1)
1 , X
(1)
2 , X
(1)
3 ) has mean (0, 0, 0) and covariance matrix
Σ1 :=

 1 ρ1f1 f1/
√
2
ρ1f1 1 −ρ′
f1/
√
2 −ρ′ 1

 , (9)
for fs =
√
pisn1
pisn1+n2
=
√
pist1
pist1+1−t1
and ρ′ = (ρ2 − ρ1)/
√
2. Summarizing the above argument, we
have shown
P (∆S ∈ CI, S = 1) = PQ,n1,n2
{
(X
(1)
1 , X
(1)
2 , X
(1)
3 ) ∈ R1(ρ1, c, d, δ1, δ2)
}
,
for R1 defined in Section 4.3. We will show below that the vector (X
(1)
1 , X
(1)
2 , X
(1)
3 ) converges to a
multivariate normal distribution, uniformly overQ as (n1, n2)→∞, in a sense we define formally
below.
Consider the term in the sum in (7) corresponding to S = 2. Analogous arguments as above
show that
P (∆S ∈ CI, S = 2) = PQ,n1,n2
{
(X
(2)
1 , X
(2)
2 , X
(2)
3 ) ∈ R2(ρ1, c, d, δ1, δ2)
}
,
for
X
(2)
1 =
√
pi2n1 + n2
σ2
{
∆ˆ2 −∆2
}
,
X
(2)
2 = Z
(1)
∗ −
√
n1∆∗
σ∗
,
X
(2)
3 =
1√
2
{(
Z
(1)
1 −
√
pi1n1∆1
σ1
)
−
(
Z
(1)
2 −
√
pi2n1∆2
σ2
)}
.
The vector (X
(2)
1 , X
(2)
2 , X
(2)
3 ) has mean (0, 0, 0) and covariance matrix
Σ2 :=

 1 ρ2f2 −f2/
√
2
ρ2f2 1 −ρ′
−f2/
√
2 −ρ′ 1

 . (10)
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Lastly, consider the term in the sum in (7) corresponding to S = ∗. Analogous arguments as
above show that
P (∆S ∈ CI, S = ∗) = PQ,n1,n2
{
(X
(∗)
1 , X
(∗)
2 , X
(∗)
3 ) ∈ R∗(ρ1, c, d, δ1, δ2)
}
,
where
(X
(∗)
1 , X
(∗)
2 ) =
(√
n1 + n2
σ∗
{
∆ˆ∗ −∆∗
}
, Z(1)∗ −
√
n1∆∗
σ∗
)
,
and we let X
(∗)
3 denote a random variable that is independent of (X
(∗)
1 , X
(∗)
2 ), and that has a stan-
dard normal distribution. We add in this exogenous variable so that all of our random vectors
below have three components, which allows a simpler exposition. The vector (X
(∗)
1 , X
(∗)
2 , X
(∗)
3 )
has mean (0, 0, 0) and covariance matrix
Σ∗ :=

 1
√
t1 0√
t1 1 0
0 0 1

 . (11)
By the uniform central limit theorem of Go¨tze (1991), under the assumptions in Section 3.1,
we have for each s ∈ {1, 2, ∗}
lim
n1,n2→∞
sup
Q∈Q,C∈C
∣∣∣∣PQ,n1,n2 {Σ−1/2s (X(s)1 , X(s)2 , X(s)3 )t ∈ C}−
∫
C
dΦ3
∣∣∣∣ = 0, (12)
where C denotes the set of all Borel measurable, convex subsets of R3, Φ3 is the distribution
function of the multivariate normal distribution in R3 with zero mean and covariance matrix the
identity matrix, and the superscript t indicates the transpose. Since we showed above that for
each s ∈ {1, 2, ∗}, P (∆S ∈ CI, S = s) = PQ,n1,n2
{
(X
(s)
1 , X
(s)
2 , X
(s)
3 ) ∈ Rs(ρ1, c, d, δ1, δ2)
}
, for
Rs(ρ1, c, d, δ1, δ2) the rectangular region in R
3 defined in (4.3), the above display (12) implies
lim
n1,n2→∞
sup
Q∈Q
∣∣∣∣P (∆S ∈ CI, S = s)−
∫
Σ
−1/2
s Rs(ρ1,c,d,δ1,δ2)
dΦ3
∣∣∣∣ = 0. (13)
We point out that Σs, ρ1, c, δ1, δ2 are each functions of pi1, n1, n2, and Q. The integral in (13)
equals P [Gs(pi1, t1, ρ1) ∈ Rs(ρ1, c, d, δ1, δ2)], for Gs a multivariate normal random vector with
mean vector (0, 0, 0) and covariance matrix Σs. Therefore,
lim
n1,n2→∞
sup
Q∈Q
|P (∆S ∈ CI, S = s)− P [Gs(pi1, t1, ρ1) ∈ Rs(ρ1, c, d, δ1, δ2)]| = 0. (14)
Combining the above with (7) implies
lim
n1,n2→∞
sup
Q∈Q
∣∣∣∣∣∣P (∆S ∈ CI)−
∑
s∈{1,2,∗}
P [Gs(pi1, t1, ρ1) ∈ Rs(ρ1, c, d, δ1, δ2)]
∣∣∣∣∣∣ = 0. (15)
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This implies
lim inf
n1,n2→∞
inf
Q∈Q
P (∆S ∈ CI) = lim inf
n1,n2→∞
inf
Q∈Q
∑
s∈{1,2,∗}
P [Gs(pi1, t1, ρ1) ∈ Rs(ρ1, c, d, δ1, δ2)] . (16)
Recall that by the definition of c in (6), we have∑
s∈{1,2,∗}
P [Gs(pi1, t1, ρ1) ∈ Rs(ρ1, c, d, δ1, δ2)] ≥ 0.95,
which together with (16) proves that the confidence interval procedure (4) satisfies (1), completing
the proof.
A.2. Proof that c as defined in (6) is smallest possible
We prove that for any continuous function c′ that maps (pi1, t1, ρ1) into R, if the confidence interval
CI in (4), except replacing c by c′, has property (1), then c′(pi1, t1, ρ1) ≥ c(pi1, t1, ρ1) at every
(pi1, t1, ρ1).
Consider any continuous function c′ that maps (pi1, t1, ρ1) into R, for which the confidence
interval CI in (4), except replacing c by c′ (which we refer to in what follows as confidence
interval procedure CI ′), has property (1). For sake of contradiction, assume there is a vector of
values (p˜i1, t˜1, ρ˜1), for which c
′(p˜i1, t˜1, ρ˜1) < c(p˜i1, t˜1, ρ˜1). Then by the definition of the function c
in (6), there exist values δ˜1, δ˜2 ∈ R for which∑
s∈{1,2,∗}
P
[
Gs(p˜i1, t˜1, ρ˜1) ∈ Rs(ρ˜1, c′(p˜i1, t˜1, ρ˜1), d, δ˜1, δ˜2)
]
< θ < 0.95, (17)
for some θ.
We first consider the case in which all components of (p˜i1, t˜1, ρ˜1) are rational numbers. We will
construct a sequence of sample sizes (n
(k)
1 , n
(k)
2 ) tending to infinity and data generating distribu-
tions Q(k) ∈ Q for which the confidence interval procedure CI ′ has coverage probability less than
θ for each k. Since (p˜i1, t˜1, ρ˜1) are assumed to be rational numbers, there exist positive integers
j1, j2 such that t˜1 = j1/(j1 + j2), and such that both j1p˜i1 and j1(1− p˜i1) are positive integers. For
each positive integer k, define:
i. the kth pair of first and second stage sample sizes to be n
(k)
1 = kj1, n
(k)
2 = kj2;
ii. the outcome distribution for subpopulation 1, Q
(k)
1a , for each a ∈ {0, 1}, to be a normal
distribution with mean 2aδ˜1{(1− p˜i1)ρ˜21/(p˜i1n(k)1 )}1/2 and variance (1− p˜i1)ρ˜21;
iii. the outcome distribution for subpopulation 2, Q
(k)
2a , for each a ∈ {0, 1}, to be a normal
distribution with mean 2aδ˜2{p˜i1(1− ρ˜21)/((1− p˜i1)n(k)1 )}1/2 and variance p˜i1(1− ρ˜21).
15
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Define the kth data generating distribution Q(k) =
(
Q
(k)
10 , Q
(k)
11 , Q
(k)
20 , Q
(k)
21
)
. We constructed the
sample sizes and data generating distributions above so that for each k, the covariance of the
corresponding stage one z-statisticsZ
(1)
1 , Z
(1)
∗ equals ρ˜1, which follows since this covariance equals√
p˜i1σ1(Q
(k))/σ2(Q
(k))
=

 p˜i1
(
σ2(Q
(k)
10 ) + σ
2(Q
(k)
11 )
)
p˜i1
(
σ2(Q
(k)
10 ) + σ
2(Q
(k)
11 )
)
+ p˜i1
(
σ2(Q
(k)
20 ) + σ
2(Q
(k)
21 )
)


1/2
=
[
2p˜i1(1− p˜i1)ρ˜21
2p˜i1(1− p˜i1)ρ˜21 + 2(1− p˜i1)p˜i1(1− ρ˜21)
]1/2
= ρ˜1,
and so that the corresponding non-centrality parameters equal δ˜1, δ˜2, which follows since the non-
centrality parameter corresponding to subpopulation 1 equals√
p˜i1n
(k)
1 ∆1(Q
(k))/σ1(Q
(k)) =
√
p˜i1n
(k)
1
[
2δ˜1{(1− p˜i1)ρ˜21/(p˜i1n(k)1 )}1/2
]
/
[
4(1− p˜i1)ρ˜21
]1/2
= δ˜1,
and a similar argument shows the non-centrality parameter corresponding to subpopulation 2
equals δ˜2.
By construction, the outcome distributions are normal, and by the assumptions in Section 3.1,
this implies that for each s ∈ {1, 2, ∗}, the vector of statistics (X(s)1 , X(s)2 , X(s)3 ) defined in Ap-
pendix A.1 has a multivariate normal distribution. We then have, by the arguments in Appendix
A.1, that for each s ∈ {1, 2, ∗}, under confidence interval procedure CI ′,
P
Q(k),n
(k)
1 ,n
(k)
2
(∆S ∈ CI ′, S = s)
= P
Q(k),n
(k)
1 ,n
(k)
2
{
(X
(s)
1 , X
(s)
2 , X
(s)
3 ) ∈ Rs(ρ˜1, c′(p˜i1, t˜1, ρ˜1), d, δ˜1, δ˜2)
}
= P
[
Gs(p˜i1, t˜1, ρ˜1) ∈ Rs(ρ˜1, c′(p˜i1, t˜1, ρ˜1), d, δ˜1, δ˜2)
]
.
Therefore, by (7) and (17), we have
P
Q(k),n
(k)
1 ,n
(k)
2
(∆S ∈ CI ′) =
∑
s∈{1,2,∗}
P
[
Gs(p˜i1, t˜1, ρ˜1) ∈ Rs(ρ˜1, c′(p˜i1, t˜1, ρ˜1), d, δ˜1, δ˜2)
]
.
< θ
< 0.95.
We have shown the coverage probability at each Q(k), n
(k)
1 , n
(k)
2 is less than θ. Since θ < 0.95, this
shows the confidence interval procedure CI ′ does not have uniform coverage probability property
(1). This completes the proof for the case in which all components of (p˜i1, t˜1, ρ˜1) are rational
numbers. In general, the vector (p˜i1, t˜1, ρ˜1) can be approximated by a sequence of vectors with
rational components, and applying the above arguments at each vector in this sequence, and using
the assumed continuity of c′, the general result follows.
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A.3. Computing c(pi1, t1, ρ1) to any desired accuracy
We describe how to compute the expansion factor c at a given vector (pi1, t1, ρ1), to any desired
accuracy, in the following sense: for any pi1, t1, ρ1, and any tolerance  > 0, we show how to
compute a value c satisfying conditions (i) and (ii) in Section 4.3.
We first outline the algorithm for computing c, and then give the details of the procedure
below. The outer loop in the procedure is a binary search over candidate values c˜ for c(pi1, t1, ρ1).
We initialize the lower bound for candidate values c˜ of c(pi1, t1, ρ1) to be 1, since as argued in
Appendix A.1, c(pi1, t1, ρ1) ≥ 1; we describe how we initialize the corresponding upper bound
below. For a given candidate c˜, we compute an approximation (as described below) of
inf
δ˜1,δ˜2∈R
∑
s∈{1,2,∗}
P
[
Gs(pi1, t1, ρ1) ∈ Rs(ρ1, c˜, d, δ˜1, δ˜2)
]
(18)
and see how it compares to 0.95+ . If the approximation to the above display is less than 0.95+ ,
we set c˜ to be the new lower bound in our search; else, we set c˜ to be the new upper bound in
our search. We then take the midpoint of the current lower and upper bounds in our search as the
next candidate value of c˜, and iterate the above procedure until the upper and lower bounds of our
search are less than  apart; we let c be the upper bound after the search terminates.
We now describe how we initialize the upper bound for candidate values c˜ of c(pi1, t1, ρ1) in the
above search. We compute the approximation (as described below) to (18) at c˜ = 1.1, (1.1)2, (1.1)3, . . .,
proceeding until the first time the approximation to (18) is greater than 0.95+ , at which point we
initialize the upper bound to the corresponding value of c˜.
We now describe how we approximate (18) to accuracy±, for given pi1, t1, ρ1, c˜. We do a grid
search, where we compute the summation in (18), for each pair (δ˜1, δ˜2) ∈ H(), where H() is
a sufficiently fine grid of points in R2 that we define below; we then output the minimum value
found, i.e.,
min
(δ˜1,δ˜2)∈H()
∑
s∈{1,2,∗}
P
[
Gs(pi1, t1, ρ1) ∈ Rs(ρ1, c˜, d, δ˜1, δ˜2)
]
. (19)
Each computation of the summation in the above display can be computed by statistical software
for computing the distribution function of a multivariate normal distribution; in our computations,
we used the mvtnorm package in R. R code for this computation is given in the Supplementary
Materials.
It remains to define the grid H() ⊂ R2, so that (19) is within  of (18). We make the change
of variables x1 = d− (ρ1δ˜1+ ρ2δ˜2), x2 = (δ˜2− δ˜1)/
√
2 to make the following explanation clearer.
Also, for each s ∈ {1, 2, ∗}, define
hs(x1, x2) = P
[
Gs(pi1, t1, ρ1) ∈ Rs(ρ1, c˜, d, δ˜1(x1, x2), δ˜2(x1, x2)
]
, (20)
where δ˜j(x1, x2) is the value of δ˜j according to the above change of variables. With a slight abuse
of notation, we additionally define hs for x1, x2 taking values −∞ or ∞, by which we mean the
corresponding limit of (20), e.g., for x1 ∈ R,
hs(x1,−∞) = lim
x′2→−∞
hs(x1, x
′
2); and hs(∞,∞) = lim
x′1→∞,x
′
2→∞
hs(x
′
1, x
′
2).
17
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Define the vector g = (g1, g2) to be the gradient with respect to x1, x2 of
∑
s∈{1,2,∗} hs(x1, x2).
For for each j ∈ {1, 2} define g˜j = supx1,x2∈R |gj|; these values can be upper bounded using the
method in Section F of the Supplementary Materials of (Rosenblum and van der Laan, 2011). Then
for any two points (x1, x2) and (x
′
1, x
′
2) in R
2, by the mean value theorem,∣∣∣∣∣∣
∑
s∈{1,2,∗}
hs(x1, x2)−
∑
s∈{1,2,∗}
hs(x
′
1, x
′
2)
∣∣∣∣∣∣ ≤ |x1 − x′1|g˜1 + |x2 − x′2|g˜2. (21)
Define the grid of values of (x1, x2) to be H
′() = H ′1()×H ′1(), for
H ′1() = {−∞} ∪ {Φ−1(/6),Φ−1(/6) + γ, . . . ,Φ−1(/6) + kγ,Φ−1(1− /6)} ∪ {∞},
where we set γ = /(2max{g˜1, g˜2}) and k = b{Φ−1(1 − /6) − Φ−1(/6)}/γc. Define the grid
H() to be that corresponding to H ′(), inverting the change of variables above that maps pairs
(δ˜1, δ˜1) to (x1, x2).
We now show that the above grid leads to an approximation of (18) to accuracy ±, i.e., that
min
(x1,x2)∈H′()
∑
s∈{1,2,∗}
hs(x1, x2)− inf
(x1,x2)∈R2
∑
s∈{1,2,∗}
hs(x1, x2) ≤ . (22)
It suffices to show for every pair (x1, x2) ∈ R2, that there is a point (y1, y2) in the grid H ′() such
that ∑
s∈{1,2,∗}
hs(x1, x2) ≥
∑
s∈{1,2,∗}
hs(y1, y2)− . (23)
For each (x1, x2) ∈ R2, we construct such a point (y1, y2), as follows: for each j ∈ {1, 2}, define
yj =


−∞, if xj < Φ−1(/6)
argminz∈H′1() |z − xj| if Φ−1(/6) ≤ xj ≤ Φ−1(1− /6)∞, if xj > Φ−1(1− /6).
That is, if xj is contained in the interval [Φ
−1(/6),Φ−1(1− /6)], we set yj to be the closest point
in the grid H ′1(); otherwise, we set yj to be ±∞, where the sign equals that of xj . We will show
the point (y1, y2) ∈ H ′() satisfies (23).
We have for any (x1, x2) ∈ R2 for which x1 ∈ [Φ−1(/6),Φ−1(1− /6)], that y1 is the nearest
point to x1 in the one-dimensional grid H
′
1(), and we have∣∣∣∣∣∣
∑
s∈{1,2,∗}
hs(x1, x2)−
∑
s∈{1,2,∗}
hs(y1, x2)
∣∣∣∣∣∣ ≤ /2, (24)
which follows by (21) and our choice of the grid width γ. An analogous result holds for any
(x1, x2) ∈ R2 for which x2 ∈ [Φ−1(/6),Φ−1(1− /6)].
For any x1 ∈ R ∪ {−∞,∞}, for any x2 < Φ−1(/6), it follows by the form of the regions
R1, R2, R∗ defined in Section 4.3 that for any s ∈ {1, 2, ∗},
|hs(x1, x2)− hs(x1,−∞)| ≤ /6. (25)
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Similarly, for any x1 ∈ R ∪ {−∞,∞}, for any x2 > Φ−1(1− /6), for any s ∈ {1, 2, ∗}, we have
|hs(x1, x2)− hs(x1,∞)| ≤ /6. (26)
Analogous results hold if we interchange x1 and x2.
By (24), (25), and (26), we have∣∣∣∣∣∣
∑
s∈{1,2,∗}
hs(x1, x2)−
∑
s∈{1,2,∗}
hs(y1, x2)
∣∣∣∣∣∣ ≤ ,
which proves (23). This completes the verification of (22), that the above grid is sufficiently fine
so as to guarantee (19) is within  of (18).
We now prove that the binary search algorithm in the second paragraph of this appendix leads
to a value c satisfying the approximation conditions (i) and (ii) in Section 4.3. The algorithm
maintains, at every iteration, that the value of (19) is at least 0.95+  for c˜ equal to the upper bound
in the search. Then by (22), we have (18) is at least 0.95 at c˜ = c, which implies condition (i).
The lower bound for candidate values c˜ of c(pi1, t1, ρ1) in our binary search algorithm is ini-
tialized to 1, and as argued in beginning of Appendix A.1, the value of (18) at c˜ = 1 is at most
0.95. By the structure of the above algorithm, whenever the lower bound for candidate values c˜
of c(pi1, t1, ρ1) is updated, the corresponding value of (19) must be less than 0.95 + . It follows
from (19) being greater or equal to (18) at any c˜, that the value of (18) is less than 0.95 +  for c˜
equal to the lower bound in the search, at any iteration of the search. Therefore, the lower bound
in the search is always at most the value of (6) with 0.95 replaced by 0.95 + . By the termination
condition of the binary search, i.e., that the upper and lower bounds be within  of each other, we
have c is at most  plus the value of (6) with 0.95 replaced by 0.95 + , which shows condition
(ii) is satisfied. We have demonstrated that c satisfies the approximation conditions (i) and (ii) in
Section 4.3.
The above binary search algorithm assumed that computation of the terms in the summation
in (19), at any fixed values of δ˜1, δ˜2, can be done without error. Since computing each such term
involves integration, in practice there will be some error, which can be made small by integrating
over a fine partition. The above algorithm can be modified to handle such error, if each term in the
summation in (19) is computed to within ±/4, if the binary search algorithm uses 0.95 + /2 as
a threshold instead of 0.95 + , and if the grid H() in (19) is replaced by the finer grid H(/4).
Then the approximation conditions (i) and (ii) in Section 4.3 hold for the modified algorithm.
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